Cancer, Sars-CoV2
Conditions
Keywords
COVID-19, Oncology, Epidemiology, Predictive factors
Brief summary
National multicentre epidemiological study to describe retrospectively and prospectively the clinical outcomes of patients with a suspected coronavirus infection (either confirmed or not) while receiving a medical treatment for the underlying cancer
Interventions
None listed
Sponsors
Centre Leon Berard
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
I1. Confirmed diagnosis of any type of solid or hematologic tumor; I2. Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ; I3. Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (\>38°C) and/or respiratory tract symptoms), either confirmed or not. Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging. Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not) ; I4. Patient and/or family did not decline data collection after complete information.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mortality of cancer patients under active anticancer treatment | 28 days after the date of the diagnostic procedure | Mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Patients' characteristics | At the date of the diagnostic procedure | To describe accurately patients' characteristics in terms of demographics |
| Overall survival | 6 months (i.e. at the the time of last patient last visit) | Overall survival will be defined as the time from the date of the first diagnostic procedure (either diagnostic test or chest imaging) to the date of death due to any cause. |
| Hospitalizations | 28 days after the date of the diagnostic procedure | The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients) |
| Death | 6 months (i.e. at the the time of last patient last visit) | Cause of death, related or not to the COVID-19 |
| Complications | 28 days after the date of the diagnostic procedure | Associated complications described by their type |
Countries
France
Outcome results
None listed